Danicopan add-on therapy in PNH, neural networks to identify bone marrow cells, and RNA editome and hematopoiesis

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Bringing Kashmir’s lakes back to life 25 min · 23 Sep 2026 · The Documentary Podcast

Soup 56 min · 23 Sep 2026 · Three Bean Salad

AFL Record Editor Ash Browne | Grand Final edition on sale now! (23.09.26) 2 min · 23 Sep 2026 · Whateley

NPR News: 09-22-2026 8PM EDT 4 min · 23 Sep 2026 · NPR News Now

Send Me To Sleep | Aristotle 44 min · 23 Sep 2026 · Send Me To Sleep

Finding the balance between offence & defence | The Art of Coaching with Ken Hinkley! (23.09.26) 5 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded18 Nov 2021

Publisherfeeds.transistor.fm ↗

Handlerec:11742113

Show notes

In this week’s episode, we’ll review results of a phase 2 study showing the beneficial effects of a first-in-class factor D inhibitor as add-on therapy in PNH patients who remain anemic and are transfusion-dependent despite C5 inhibition. Next, we’ll review the work of researchers who have developed a neural network that they say is highly accurate in differentiating between bone marrow cell morphologies. We’ll close with a report demonstrating that RNA editing of antizyme inhibitor 1, or Azin1, is a novel regulator of hematopoietic cell fate that can influence self-renewal and differentiation.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in